Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens.
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment linear model with combined proportional and additive residual unknown variability. The volume of distribution of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m 2 would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 2×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundAPACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Self-citationComparison of Dopamine and Norepinephrine in the Treatment of Shock
De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907118 · Cited by 1,940 · cited 1×
“The morbidity and mortality rates for sepsis and septic shock remain unacceptably high, with septic shock still associated with a 35 to 65% in-hospital mortality rate (5, 9).”
BackgroundSelf-citationInadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805 · cited 1×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795 · cited 2×
“The aim of this regimen was to provide serum drug concentrations between 20 and 30 mg/liter (28).”
BackgroundMethodAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Consensus supports the view that the pharmacokinetic-pharmacodynamic parameter best correlated with the efficacy of vancomycin is the AUC0–24-to-MIC (AUC0–24/ MIC) ratio (8, 11, 29).”
BackgroundPharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862 · cited 1×
“Augmented renal clearance is common in hyperdynamic critically ill patients and may increase the risk for subtherapeutic vancomycin exposure (27, 31).”
BackgroundSelf-citationRybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Clinical Infectious Diseases · doi:10.1086/600877 · Cited by 815 · cited 9×
“We use the term “pseudo-steady-state” because whether steady state is ever achieved in ICU patients with sepsis is debatable.”
BackgroundInfluentialThe Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774 · cited 1×
“Consensus supports the view that the pharmacokinetic-pharmacodynamic parameter best correlated with the efficacy of vancomycin is the AUC0–24-to-MIC (AUC0–24/ MIC) ratio (8, 11, 29).”
BackgroundMoise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757 · cited 3×
“(22) for MRSA pneumonia suggest that standard dosing approaches are unlikely to achieve the required pharmacodynamic index of vancomycin exposure needed for optimal activity.”
BackgroundGarnacho-Montero, J., Garcia-Garmendia, J. L., Barrero-Almodovar, A., Jimenez-Jimenez, F. J., Perez-Paredes, C., & Ortiz-Leyba, C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000098031.24329.10 · Cited by 718 · cited 1×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundBlot, S. I., Vandewoude, K. H., Hoste, E. A., & Colardyn, F. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2229 · Cited by 463 · cited 1×
“8% of bacteremias are due to MRSA (4), with mortality rates for MRSA bacteremia in critically ill patients being reported as between 45 and 55% (3, 13).”
BackgroundAdult-population incidence of severe sepsis in Australian and New Zealand intensive care units
Finfer, S., Bellomo, R., Lipman, J., French, C., Dobb, G., & Myburgh, J. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2157-0 · Cited by 442 · cited 2×
“Of significant concern for clinicians is the increasing prevalence of multidrug-resistant bacteria, particularly methicillinresistant Staphylococcus aureus (MRSA), which has been found to be the causative pathogen in more than 10% of infections resulting in septic shock (9).”
BackgroundSelf-citationWysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2460-2467.2001 · Cited by 385 · cited 3×
“Previous clinical outcome studies have shown equivalent outcomes for vancomycin administered by either approach (33).”
BackgroundMethodResultInfluentialAugmented Renal Clearance: Implications for Antibacterial Dosing in the Critically Ill
Udy, A. A., Roberts, J. A., Boots, R. J., Paterson, D. L., & Lipman, J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318140-000000000-00000 · Cited by 377
Self-citationParke, J., Holford, N. H. G., & Charles, B. G. (1999) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(98)00098-4 · Cited by 350 · cited 1×
“A nonparametric bootstrap method (23) (n 1,000) was used to”
MethodBurton, D. C. (2009) · JAMA · doi:10.1001/jama.2009.153 · Cited by 249
Jeffres, M. N., Isakow, W., Doherty, J. A., McKinnon, P. S., Ritchie, D. J., Micek, S. T., & Kollef, M. H. (2006) · Chest · doi:10.1378/chest.130.4.947 · Cited by 219
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients
del Mar Fernández de Gatta Garcia, M., Revilla, N., Calvo, M. V., Domínguez-Gil, A., & Sánchez Navarro, A. (2007) · Intensive Care Medicine · doi:10.1007/s00134-006-0470-5 · Cited by 169
Vancomycin dosing in morbidly obese patients
Bauer, L. A., Black, D. J., & Lill, J. S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050524 · Cited by 162 · cited 1×
“Data supporting the strong relationship between vancomycin volume of distribution and TBW have been described in various vancomycin pharmacokinetic studies, particularly in obese patients (1).”
BackgroundAminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients
Marik, P. E. (1993) · Anaesthesia and Intensive Care · doi:10.1177/0310057x9302100206 · Cited by 145 · cited 1×
“Curiously, we did not observe an effect of the level of sickness severity on volume of distribution, as has previously been described for aminoglycosides (20).”
ResultPea, F., Furlanut, M., Negri, C., Pavan, F., Crapis, M., Cristini, F., & Viale, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01149-08 · Cited by 118
Population pharmacokinetic parameters of vancomycin in critically ill patients
Llopis-Salvia, P., & Jiménez-Torres, N. V. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00762.x · Cited by 114 · cited 1×
“4 liters/kg [19]) compared with that of aminoglycosides ( 0.”
ResultMatthews, I., Kirkpatrick, C. M. J., & Holford, N. H. G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02114.x · Cited by 110 · cited 1×
“5% percentile) for the parameters, as described previously (21).”
MethodPea, F., Porreca, L., Baraldo, M., & Furlanut, M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.3.329 · Cited by 100
Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections
Giuliano, C. A., Haase, K. K., & Hall, R. G. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.123 · Cited by 91 · cited 1×
“Consensus supports the view that the pharmacokinetic-pharmacodynamic parameter best correlated with the efficacy of vancomycin is the AUC0–24-to-MIC (AUC0–24/ MIC) ratio (8, 11, 29).”
BackgroundMethicillin resistant Staphylococcus aureus in the critically ill
Hardy, K. J., Hawkey, P. M., Gao, F., & Oppenheim, B. A. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeh008 · Cited by 89
DeRyke, C. A., & Alexander, D. P. (2009) · Hospital Pharmacy · doi:10.1310/hpj4409-751 · Cited by 63 · cited 1×
“Conventional dosing regimens of 500 mg every 6 h or 1 g every 12 h have little evidence supporting their efficacy (7), while data from the work of Moise-Broder et al.”
MethodA higher dose of vancomycin in continuous infusion is needed in critically ill patients
Jeurissen, A., Sluyts, I., & Rutsaert, R. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.09.004 · Cited by 57 · cited 1×
“Such an approach to dosing will increase the likelihood of achieving vancomycin concentrations associated with improved antimicrobial activity and, potentially, positive clinical outcomes (15, 22).”
BackgroundHo, K. M., & Robinson, J. O. (2009) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0903700320 · Cited by 34 · cited 1×
“8% of bacteremias are due to MRSA (4), with mortality rates for MRSA bacteremia in critically ill patients being reported as between 45 and 55% (3, 13).”
BackgroundAppropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia
Potoski, B. A., & Paterson, D. L. (2007) · CHEST Journal · doi:10.1378/chest.06-2839 · Cited by 6 · cited 1×
“(14) have shown that trough concentrations from intermittent dosing are correlated with AUC and thus are regarded as an appropriate surrogate measure for the AUC0–24 and as the most practical method to monitor vancomycin dosing (26, 28).”
MethodMethicillin-Resistant Staphylococcus aureus Pneumonia Treatment
Moine, P., & Bédos, J. (2007) · CHEST Journal · doi:10.1378/chest.06-2730 · Cited by 2
Research works printed but not linked: 1
- BealS. L. SheinerL. B.. 1998. NONMEM user guides (I-VIII). University of California at San Francisco, San Francisco, CA.
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationKalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationRybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
“Loading doses of 25 to 35 mg/kg will require infusion times of at least 2 to 3 hours.(99) After administration of the loading dose, the initiation of the maintenance dose should occur at the next dosing interval (eg, an interval of every 6 hours indicates initiating the maintenance dose 6 hours after the start of the…”
BackgroundRoberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
“Critically ill patients have altered volumes of distribution for antibiotics [19, 20], and, unlike other patient groups, need larger initial doses to rapidly achieve therapeutic concentrations [21].”
BackgroundSelf-citation
Metadata
- Authors
- Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Roberts, Jason A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-06
- Volume
- 55
- Issue
- 6
- Pages
- 2704-2709
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3101407
- OpenAlex
- W2161342563
- Semantic Scholar
- 6a21d1534090532b1e164a9fa3b5932d1c6a8db8
- Cited by
- 226
- References
- 35
- Citations by year
- 2026: 14 · 2025: 5 · 2024: 9 · 2023: 16 · 2022: 19 · 2021: 12 · 2020: 18 · 2019: 14 · 2018: 8 · 2017: 21 · 2016: 15 · 2015: 9 · 2014: 18 · 2013: 25 · 2012: 18
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- vancomycin, population pharmacokinetics, continuous infusion, critically ill patients, sepsis, loading dose, renal clearance, creatinine clearance, dose adjustment, target attainment, Gram-positive bacterial infections, Monte Carlo simulation
- MeSH terms
- Adult, Aged, Anti-Bacterial Agents, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Retrospective Studies, Vancomycin, Critical Illness, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.